- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
To understand triple negative breast cancer, we first have to understand how breast cancer is classified. Breast tumors are broadly classified into three major subtypes: estrogen receptor (ER)- and/or progesterone receptor (PR)-positive, HER2 receptor positive or triple negative.
Triple negative breast cancer is an aggressive disease with a high likelihood of spreading to other tissues, a process called metastasis. TNBC is primarily treated with chemotherapy.
Triple negative breast cancer (TNBC) is so named because TNBC cells lack the three common breast tumor markers: estrogen receptor, progesterone receptor and the HER2 protein. Unlike breast cancers with these markers, there are currently no FDA-approved targeted therapies for TNBC.
Triple negative breast cancer (TNBC) comprises 15-20 percent of all breast cancers, but few treatment options exist outside of chemotherapy.
Blood Test Provides Important Prognostic Information for Metastatic Triple Negative Breast Cancer Patients
Using only a blood test, researchers have identified a biomarker that can predict prognosis in patients with metastatic triple negative breast cancer (mTNBC).
Most clinical studies collect blood, tumor samples, or other tissue from participants. While this data is important for the study at hand, the samples may help future studies as well.
Dr. Leisha Emens is at the Johns Hopkins Kimmel Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy.
After studying immunology as a graduate student, Dr. Robert Vonderheide was so amazed by its complexity and potential in medicine that he decided to go to medical school. As a medical oncologist, Dr.
To mark Triple Negative Breast Cancer Day, BCRF recently met with two of its expert researchers in immuno-oncology to learn more about the progress and challenges of immunotherapy in triple negative breast cancer and other